Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Abatacept (Primary) ; Ciclosporin; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms Aba NMD
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 Planned End Date changed from 1 Jan 2020 to 29 Sep 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 29 Sep 2019.